Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
325.63
-2.24 (-0.68%)
Mar 31, 2025, 1:13 PM EDT - Market open
Company Description
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
The company offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc.
Country | United States |
Founded | 2011 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 528 |
CEO | William Sibold |
Contact Details
Address: Four Tower Bridge, Suite 200 West Conshohocken, Pennsylvania 19428 United States | |
Phone | 267 824 2827 |
Website | madrigalpharma.com |
Stock Details
Ticker Symbol | MDGL |
Exchange | NASDAQ |
Stock Type | Common Stock |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001157601 |
CUSIP Number | 558868105 |
ISIN Number | US5588681057 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
William J. Sibold | Chief Executive Officer, President and Director |
Dr. Rebecca A. Taub M.D. | Founder, Chief Medical Officer, President of Research and Development and Director |
Carole Huntsman | Chief Commercial Officer |
Mardi C. Dier | Chief Financial Officer and Senior Vice President |
Mark Underwood | Senior Vice President of Business Planning and Operations |
Ronald Filippo | Chief Information Officer |
Tina E. Ventura | Chief Investor Relations Officer |
Shannon Kelley | General Counsel |
Clint Wallace | Chief Human Resources Officer |
Edward Chiang | Senior Vice President of Clinical and Technical Operations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 13, 2025 | 144 | Filing |
Mar 13, 2025 | 144/A | Filing |
Mar 12, 2025 | 144 | Filing |
Mar 11, 2025 | 8-K | Current Report |
Mar 5, 2025 | 144 | Filing |
Mar 3, 2025 | 144 | Filing |
Mar 3, 2025 | 144 | Filing |
Mar 3, 2025 | 144 | Filing |
Feb 28, 2025 | 144 | Filing |
Feb 27, 2025 | 144 | Filing |